Free­line nabs $120M, eyes IPO as its gene ther­a­py comes in­to fo­cus

Free­line Ther­a­peu­tics has land­ed an­oth­er mega-round to back its gene ther­a­py ef­forts and, on the same morn­ing of the an­nounce­ment, in­di­cat­ed that they could yet raise sig­nif­i­cant­ly more cash be­fore year’s end.

The new Se­ries C rings in at $120 mil­lion, a hair above their $112 mil­lion Se­ries B in 2018. And for the first time since Free­line’s launch, the round in­cludes promi­nent in­vestors out­side of their found­ing VC, Syn­cona, in­clud­ing No­vo Hold­ings, Even­tide As­set Man­age­ment and Welling­ton Man­age­ment Com­pa­ny. The new in­vestors are join­ing as the first clin­i­cal da­ta emerge for the com­pa­ny, with Free­line al­so say­ing to­day they would present da­ta show­ing their lead drug could bring fac­tor IX to nor­mal in se­vere he­mo­phil­ia pa­tients.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER